Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
GSK Enters Agreement to Acquire IDRx, Inc.
Details : Through this acquisition, GSK will expand its gastrointestinal cancer portfolio with IDRX-42. IDRX-42 is a highly selective KIT TKI developed for treating gastrointestinal stromal tumors.
Product Name : IDRX-42
Product Type : Other Small Molecule
Upfront Cash : $1,000.0 million
January 13, 2025
IDRx Shares Phase 1 Data for IDRX-42 in Advanced GIST at CTOS 2024
Details : IDRX-42 is a novel, KIT inhibitor that has potent activity against both the key activating mutations and broad coverage of the clinically relevant resistance mutations in KIT-driven GIST.
Product Name : IDRX-42
Product Type : Small molecule
Upfront Cash : Not Applicable
November 14, 2024
IDRx Announces $120M Series B to Advance New Treatment for Gastrointestinal Stromal Tumor
Details : The proceeds will support the ongoing clinical trial of its lead product IDRX-42l, targeting all major categories of activating & resistance mutations in patients with KIT-mutant GIST.
Product Name : IDRX-42
Product Type : Small molecule
Upfront Cash : Undisclosed
August 07, 2024
IDRx Updates Phase 1 Data Supporting IDRX-42 in GIST Patients
Details : IDRX-42 is a novel, KIT inhibitor that has potent activity against both the key activating mutations and broad coverage of the clinically relevant resistance mutations in KIT-driven GIST.
Product Name : IDRX-42
Product Type : Small molecule
Upfront Cash : Not Applicable
June 03, 2024
Details : IDRx’s pipeline includes IDRX-42 and IDRX-73, small molecule tyrosine kinase inhibitors acquired through license agreements with Merck KGaA, Darmstadt, Germany, and Blueprint Medicines, respectively.
Product Name : IDRX-42
Product Type : Small molecule
Upfront Cash : Undisclosed
August 02, 2022
Reset All
